Optimizing Post-operative Recovery in Bariatric Patients With Obstructive Sleep Apnea Undergoing Outpatient Surgery: A Comparison of Sugammadex and Neostigmine

a study on Anesthesia Obstructive Sleep Apnea Sleep Apnea Sleep Disorders

Summary

Eligibility
for people ages 18-80 (full criteria)
Location
at La Jolla, California
Dates
study started
estimated completion
Principal Investigator
by Jerry Ingrande

Description

Summary

This study assesses the efficacy of sugammadex against neostigmine for hastening recovery from neuromuscular blockade and optimizing pulmonary function in obese patients with obstructive sleep apnea presenting for outpatient surgery. Both drugs are used in anesthesiology to reverse neuromuscular blockade that is given in the setting of inducing and maintaining general anesthesia.

Keywords

Anesthesia Sleep Apnea, Obstructive Neostigmine Sugammadex

Eligibility

You can join if…

Open to people ages 18-80

  • obese (body mass index [BMI] >30 kg/m2)
  • diagnosis of obstructive sleep apnea (OSA) (with or without continuous positive airway pressure [CPAP] use)
  • scheduled for surgery requiring general anesthesia and neuromuscular blockade

You CAN'T join if...

  • history of hepatic, renal, or cardiovascular and/or cerebrovascular dysfunction
  • history of difficult tracheal intubation
  • history of adverse reaction to anesthesia
  • history of adverse reaction to rocuronium, sugammadex, and/or neostigmine/glycopyrrolate

Location

  • University of California San Diego accepting new patients
    La Jolla California 92037 United States

Lead Scientist at UCSD

  • Jerry Ingrande
    Associate Clinical Professor, Anesthesiology, Vc-health Sciences-schools. Authored (or co-authored) 21 research publications. Research interests: Pharmacokinetics · Pharmacodynamics · Clinical Pharmacology

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Diego
ID
NCT04570150
Phase
Phase 4 Research Study
Study Type
Interventional
Participants
Expecting 120 study participants
Last Updated
Contact us about this trial